WO1996030054A1 - 99mTc - LABELLED SEROTONIN RECEPTOR BINDING SUBSTANCES - Google Patents
99mTc - LABELLED SEROTONIN RECEPTOR BINDING SUBSTANCES Download PDFInfo
- Publication number
- WO1996030054A1 WO1996030054A1 PCT/US1996/004239 US9604239W WO9630054A1 WO 1996030054 A1 WO1996030054 A1 WO 1996030054A1 US 9604239 W US9604239 W US 9604239W WO 9630054 A1 WO9630054 A1 WO 9630054A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- general formula
- alkyl
- labelled
- receptor binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C**(C)N(CI(*NIC)=O)NC Chemical compound C**(C)N(CI(*NIC)=O)NC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- the present invention relates to zero-charged 99m Tc - labelled substances having a serotonin receptor binding activity, to a method of preparing these substances, to radiopharmaceutical compositions comprising these substances, to the use of these compositions for imaging purposes, and to a kit for preparing a radiopharmaceutical composition.
- serotonin receptors particularly the 5-HT 2 receptors
- brain is of interest because of the importance of altered serotoninergic neurotransmission in many neurological and psychological diseases and disorders. It was suggested from animal and human studies that serotonin receptors are involved in aging, sleep, pain, temperature control,
- PET and SPECT imaging may significantly improve our understanding of the physiology and pathophysiology of these processes and disorders and may contribute to new approaches for treatment of neurological and psychological diseases and disorders. Therefore the development of suitable radiolabelled substances for imaging serotonin receptors in brain is important.
- 5-HT receptors There are three main groups of 5-HT receptors, namely 5-HT 1 , 5-HT 2 and 5-HT 3 receptors, which are further divided into several subtypes.
- 5-HT- receptors only the ⁇ -HT 2A (previously named 5-HT 2 ) and the 5-HT 2C receptors (previously named 5-HT 1C ) are present in the brain in significant amounts.
- PET Positron Emission Tomography
- serotonin receptor imaging agents such as [ 11 C]ketanserin (Berridge et al., J. Lab. Compds. Radicpharm. 1983, 20, 73-78), N-[ 11 C-methyl]ketanserin (Frost et al., J. Nucl. Med.
- radionuclide 123 I is not the radionuclide of choice for imaging purposes, because this isotope has the main disadvantage of being not readily available in the hospital (no generator nuclide and a relatively short half-life).
- the most suitable radionuclides are metal-radio ⁇ uclides, in particular the generator nuclide 99m Tc, having an optimum half-life and superior radiation characteristics. Therefore a 99m Tc - labelled substance for serotonin receptor imaging is by far the preferred agent for diagnosing certain neurological and psychological diseases and disorders. Ballinger et al. (Appl. Radiat.
- X and X' are each individually O or S;
- R 4 is a hydrogen atom or a (C 1 -C 6 )alkyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, oxo, [N-mono- or N,N-di(C 1 - C 3 )alkyl]-amino, (C 1 -C 3 ) alkyl, (C 1 -C 3 ) alkoxy and optionally substituted phenyl;
- R 4 ' is a covalent bond to A
- R 1 and R 2 are each independently a biradical of the general formula or
- R 6 , R 7 or R 8 are each individually selected from the group consisting of hydrogen, (C 1 -C 3 )alkyl, (C 1 - C 3 )alkoxy and fluoro, or wherein R 6 and R 7 together constitute an oxo group; and
- B and t are each individually 0, 1 or 2, with the proviso that s and t together are 1 or 2;
- R 3 is a substituent selected from the group consisting of substituted or unsubstituted (C 1 -
- Tc is 99m Tc
- A is a 2- to 8-memibered hydrocarbon biradical, wherein the carbon atoms may be interrupted by one or two heteroatoms selected from O and S;
- B is an N-(C 1 -C 4 )alkyl group, an NH group, or an optionally substituted piperidin-derived, piperazin-derived, morpholin-derived or pyrrolidin-derived biradical;
- E is selected from the following groups:
- p is an integer from 0 to 4.
- q is an integer from 0 to 3;
- r is an integer from 0 to 1;
- T is O or H 2 ;
- Ar and Ar' are each independently unsubstituted or substituted aryl or heteroaryl groups, wherein the aryl or heteroaryl groups are selected from phenyl, pyridyl, pyrrolyl, triazinyl, pyridazinyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, benzofuranyl and benzisoxazolyl, and wherein the substituents are selected from halogen, trifluoromethyl, (C 1 -C 4 )alkyl and (C 1 -C 4 )alkoxy;
- E together with B constitutes an optionally substituted 2,4-dihydroquinazolyl group attached with its (3-N)atom to A.
- Suitable substituents of the piperidin, piperazin, morpholin or pyrrolidin moiety are halogen, (C 1 -C 3 )alkyl and (C 1 -C 3 )alkoxy.
- p is an integer from 0 to 4.
- q is an integer from 0 to 3;
- r is an integer from 0 to 1;
- T is O or H 2 ;
- Ar" is a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, (C 1 -C 4 )alkyl and (C 1 -C 4 )alkoxy.
- X and X' are each individually O or S;
- Y is S or NR 4 "
- R 4 " is a hydrogen atom or a (C 1 -C 4 )alkyl group
- Y'" is NR 4 '
- R 4 ' is a covalent bond to A
- R 1 and R 2 are each independently a biradical of the general formula
- R 6 and R 7 are each individually selected from the group consisting of hydrogen, methyl, and fluoro, or wherein R 6 and R 7 together constitute an oxo group;
- s and t are each individually 0, 1 or 2, with the proviso that s and t together are 1 or 2
- R 3 is a substituent selected from the group consisting of substituted or unsubstituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, and aryl, wherein the substituents are selected from the group consisting of (C 1 -C 4 )alkyl , (C 1 -C 4 )alkoxy, halogen and trifluoromethyl;
- Tc is 99m Tc.
- Z is CH or N
- R 9 and R 10 are each individually H or (C 1 -C 3 )alkyl, or R 9 and R 10 form together a biradical of the formula -CH 2 -CH 2 -;
- u is an integer from 0 to 2;
- v is an integer from 0 to 1.
- Suitable examples of the zero-charged 99m Tc - labelled substances according to the invention are:
- the new 99m Tc - labelled substances of the invention can be prepared in a manner known per se for related compounds.
- Suitable examples of monodentate ligands of the general formula VII are represented by the formulas a to e below. These ligands can be combined, for example, with the coligands g to n:
- a suitable example of a tridentate ligand of the general formula VIIA is the above ligand of formula m.
- the present invention also relates to new ligands for chelating metal atoms, having the general formulas:
- L"' is a tridentate chelating group, as defined hereinbefore;
- A, B and E have the meanings given hereinbefore, with the proviso that in compound VII B is not an NH group when E is (C 3 )alkyl phenyl.
- the invention further relates to a radicpharmaceutical composition, comprising in addition to a pharmaceutically acceptable carrier material and, if desired, at least one pharmaceutically acceptable adjuvant, as the active substance a labelled substance as defined above.
- the invention also relates to a method for detecting and localizing tissues having serotonin receptors in the body of a warm-blooded living being, in particular in the brain of said being, which comprises (i) administering to said being a composition corrprising, in a quantity sufficient for external imaging, a 99m Tc - labelled substance as defined above, and thereupon (ii) subjecting said being to external imaging to determine the targeted sites in the body of said being in relation to the background activity.
- the method is especially useful to detect and localize tissues having serotonin receptors of the 5-HT 2A type.
- the invention also relates to a kit for preparing a radiopharmaceutical composition.
- kit according to the present invention may comprise (i) a serotonin receptor binding compound having the general formula VII together with a tridentate ligand of the general formula IX, or a serotonin receptor binding compound of the general formula VIIA together with a monodentate ligand of the general formula VIIIA, to which compounds, if desired, an inert pharmaceutically acceptable carrier and/or formulating agents and/or adjuvants is/are added, (ii) a reducing agent, and, if desired, a chelator, said ingredients (i) and (ii) optionally being combined, and (iii) instructions for use with a prescription for reacting the ingredients of the kit with 99m Tc in the form of a pertechnetate solution.
- the radionuclide 99m Tc will preferably be added separately in the form of a pertechnetate solution.
- the kit will comprise a suitable reducing agent and, if desired, a chelator, the former to reduce the pertechnetate or the perrhenate.
- a reducing agent may be used, for example, a dithionite or a metallic reducing agent.
- the ingredients may optionally be combined, provided they are compatible.
- Such a monocom- ponent kit, in which the combined ingredients are preferably lycphilized, is excellently suitable for being reacted, by the user, with the radionuclide solution.
- a metallic reducing agent for example, Sn(II), Ce(III), Fe(II), Cu(I), Ti(III) or Sb(III); Sn(II) is excellently suitable.
- the receptor binding compound of the above-mentioned kits may be supplied as a solution, for example, in the form of a physiological saline solution, or in some buffer solution, but is preferably present in a dry condition, for example, in the lycphilized condition.
- sterile in which, when the constituent is in the dry state, the user should preferably use a sterile physiological saline solution as a solvent.
- the above-mentioned constituent may be stabilized in the conventional manner with suitable stabilizers, for example, ascorbic acid, gentisic acid or salts of these acids, or it may comprise other auxiliary agents, for example, fillers, such as glucose, lactose, mannitol, and the like.
- suitable stabilizers for example, ascorbic acid, gentisic acid or salts of these acids, or it may comprise other auxiliary agents, for example, fillers, such as glucose, lactose, mannitol, and the like.
- the free base can be obtained by treating the crude above product (30 mmol) with a solution of NaHCO 3 (5 g in 30 ml water) and extracting the resultant mixture with methylene chloride (1 ⁇ 30 ml; 2 ⁇ 20 ml). After washing (15% aqueous NaCl, 20 ml) and drying, the filtrate is evaporated to dryness, after which the residue is distilled at 40 Pa to give 5.7 g of the desired product (90%) as a slightly yellow oil.
- N-(3-hydroxypropyl)-3-phenylpropylamine (23.2 g, 012 mol) is dissolved in formic acid (85%; 33g, 0.6 mol).
- formic acid 85%; 33g, 0.6 mol.
- an aqueous solution of formaldehyde (36%; 11.2 ml, 0.144 mol) is added.
- the diamine is prepared by amination of the chloro intermediate using the sodium diformylamide method described by Yinglen and Hongwen (Synthesis 1990, 112 - 124).
- the free base is obtained by treating the crude product with a solution of NaHCO 3 (8 g in 40 ml water) and extracting the resultant mixture with chloroform (1 ⁇ 35 ml, 2 ⁇ 20 ml). After washing (15% NaCl, 20 ml) and drying (MgSO 4 ) the filtrate is evaporated and the residue is distilled at 40 Pa to give 12.5 of slightly yellow oil.
- the final product is prepared according to J.L. Corbin et al. (Inorg. Chim. Acta 90 (1984) 41-51).
- a solution of N-(3-aminopropyl)-N-methyl-3-phenylproylamine (2g, 0.01 mol) in 40 ml of dry toluene is mixed with a solution of ethylene sulfide (1.3g, 0.021 mol) in 30 ml of dry toluene and allowed to stand overnight (sealed tube, argon flushed).
- the reaction mixture is heated to 130°C (bath temperature) for 15 h, cooled, and filtered to removed a small amount of polymer product.
- the solvent is removed and the crude product precipitated as hydrochloride. Recrystallization from methanol/diethyl ether yields a as a white powder.
- a vial containing a lyophilized mixture of 100 mg sodium gluconate and 0.5 mg of SnCl 2 is reconstituted with a mixture of 3ml of water and 0.5 mg of 99m Tc-pertechnetate (ca. 500 MBq).
- the resulting 99m Tc-gluconate complex is added to 1 ml of an acetonitrilic solution containing equimolar amounts of the tridentate ligand g (0.015 mmol) and the monodentate ligand s. (0.015 mmol).
- the pH is adjusted to approximately 9 with 0.1 N NaOH.
- the aqueous solution is extracted with 1 ml of diethyl ether. About 90% of the activity is recovered.
- the organic phase is washed twice with 1 ml of water and dried over Na 2 SO 4 .
- the cortex of rat brain is homogenized in 10 volumes of ice-cold Tris-buffer solution (50 mM Tris-HCl, pH 7.6) with an Ultra-Turrax R T25 homogenizer. The homogenate is centrifuged at 20,000 g for 10 min. The resulting pellet is resuspended with the Ultra-Turrax and centrifuged again at 20,000 g for 10 min. After repeating the same procedure, the pellet is resuspended in 10 volumes of buffer and stored at -20°C until use in the binding studies.
- ketanserin hydrochloride [ethylene- 3 H] (2356.9 GBq/mmol) in the presence and absence of 1 ⁇ M unlabelled mianserin, a well-known serotonin receptor antagonist just as ketanserin.
- the binding assays are terminated by rapid filtration through GF/B glass fiber filters. The filters are rapidly washed with four 4-ml portions of ice-cold buffer, transferred to 10 ml of scintillation fluid (uJtima- Gold R ) and analysed for radioactivity.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to a zero-charged 99mTc - labelled substance having a serotonin receptor binding activity, wherein the serotonin receptor binding compound is represented by the general formula (I): L - A - B - E, wherein L is a chelating moiety selected from the group consisting of a tridentate/monodentate chelating combination; A is a 2- to 8-membered hydrocarbon biradical, wherein the carbon atoms may be interrupted by one or two heteroatoms selected from O and S; B is an N-(C¿1?-C4) alkyl group, an NH group, or an optionally substituted piperidin-derived, piperazin-derived, morpholin-derived or pyrrolidin-derived biradical; and E is an aryl or heteroaryl group or wherein E together with B constitutes an optionally substituted 2,4-dihydroquinazolyl group; wherein said serotonin receptor binding compound is labelled with technetium-?99m¿ in the form of oxotechnetium (V), said technetium being attached to said compound by means of said chelating moiety. The invention also relates to a method of preparation of said labelled substance, a radiopharmaceutical composition comprising said labelled substance, a method for detecting and localizing tissues having serotonin receptors with the aid of said labelled substance and a kit for preparing a radiopharmaceutical composition containing said labelled substance.
Description
99mTc - labelled serotonin receptor binding substances
The present invention relates to zero-charged 99mTc - labelled substances having a serotonin receptor binding activity, to a method of preparing these substances, to radiopharmaceutical compositions comprising these substances, to the use of these compositions for imaging purposes, and to a kit for preparing a radiopharmaceutical composition.
Studying serotonin receptors, particularly the 5-HT2 receptors, in brain is of interest because of the importance of altered serotoninergic neurotransmission in many neurological and psychological diseases and disorders. It was suggested from animal and human studies that serotonin receptors are involved in aging, sleep, pain, temperature control,
Alzheimer disease, schizophrenia, eating disorders, anxiety, depression and suicide. PET and SPECT imaging may significantly improve our understanding of the physiology and pathophysiology of these processes and disorders and may contribute to new approaches for treatment of neurological and psychological diseases and disorders. Therefore the development of suitable radiolabelled substances for imaging serotonin receptors in brain is important.
There are three main groups of 5-HT receptors, namely 5-HT1, 5-HT2 and 5-HT3 receptors, which are further divided into several subtypes. Among the 5-HT-, receptors only the δ-HT2A (previously named 5-HT2) and the 5-HT2C receptors (previously named 5-HT1C) are present in the brain in significant amounts. For Positron Emission Tomography (PET) a number of serotonin receptor imaging agents are already available, such as [11C]ketanserin (Berridge et al., J. Lab. Compds. Radicpharm. 1983, 20, 73-78), N-[11C-methyl]ketanserin (Frost et al., J. Nucl. Med. 1987, 28 (Suppl.), 600), and [18F]altanserin (Lemaire et al., J. Nucl. Med., 1991, 32, 2266-2272). To allow a broad clinical application, however, the development of serotonin receptor imaging agents for the imaging technique of Single Photon Emission Computed Tomography (SPECT) is required. Aiming at such SPECT tracers, ketanserin (Mertens et al., WO90/11093) and certain 5-HT1A receptor antagonists, such as 4-(2'-methoxyphenyl)-1-[2'-{N-(2"-pyperidinyl)-p-iodobenzamido}ethyl]piperazine (p-MPPI) and related compounds (Zhuang et al., J. Med. Chem.,
1994, 37, 1406-1407) have been labelled with 123I.
123I, however, is not the radionuclide of choice for imaging purposes, because this isotope has the main disadvantage of being not readily available in the hospital (no generator nuclide and a relatively short half-life). The most suitable radionuclides are metal-radioπuclides, in particular the generator nuclide 99mTc, having an optimum half-life and superior radiation characteristics. Therefore a 99mTc - labelled substance for serotonin receptor imaging is by far the preferred agent for diagnosing certain neurological and psychological diseases and disorders. Ballinger et al. (Appl. Radiat. Isot., 1989, 40, 547-549) have prepared 99mTc - labelled spiperone dithiocarbamate as a potential radiopharmaceutical for dopamine receptor imaging with SPECT. Biodistribution studies, however, showed a low uptake of radioactivity in the brain. Nanjappan et al. (IXth. Intern. Symp. on Radiopharm. Chem., 1992, 69; Paper B9) have described 99mTc - labelled 3-quinuclidinyl benzylate boronic acid complexes (QNB-BATO's) as potential muscarine acetylcholinergic receptor (mAChR) tracers. Changes in mAChR density in the brain have been associated with several neurodegenerative disorders such as Alzheimer disease. The QNB-BATO stereoisomers (the synthesis results in four different stereoisomers), however, showed high nonspecific binding affinity, which makes these complexes not suitable for imaging purposes in practice. Recently, Lever et al. (Nucl. Med. Biol., 1994, 21, 157-164) have investigated related 99mTc - labelled compounds for mAChR imaging. The observed affinity for the target receptors, however, was also insufficient for clinical application as mACh receptor tracers. Finally, very recently Kung et al. (J. Nucl. Biol. Med., 1994, 38, 449-450) have disclosed some new 99mTc - N2S2-complexes as potential 5HT1A receptor imaging agents, based upon the above-described p-MPPI as the substrate, unfortunately, however, the 99mTc-p-MPP prepared did not display any brain activity in vivo experiments.
It is the objective of the present invention to provide 99mTc - labelled substances having a high and selective binding affinity to serotonin receptors, in particular to δ-HT2A receptors, which make them promising for imaging of serotonin receptor related processes, in particular neurological and psychological diseases and disorders.
This objective can be achieved, according to the present invention, by a zero-charged 99mTc - labelled substance having a serotonin receptor binding activity, wherein the serotonin receptor binding compound is represented by the general formula
L - A - B - E (I) wherein:
L is a metal labelled chelating moiety with the general formula
or
wherein:
X and X' are each individually O or S;
Y is O, S, Se, NR4, PR4 or -C(R4)=N-,
wherein R4 is a hydrogen atom or a (C1-C6)alkyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, oxo, [N-mono- or N,N-di(C1- C3)alkyl]-amino, (C1-C3) alkyl, (C1-C3) alkoxy and optionally substituted phenyl;
Y' is NR4' or PR4' or -C(R4')=N-,
wherein R4' is a covalent bond to A;
R1 and R2 are each independently a biradical of the general formula or
wherein:
R6 , R7 or R8 are each individually selected from the group consisting of hydrogen, (C1-C3)alkyl, (C1- C3)alkoxy and fluoro, or wherein R6 and R7 together
constitute an oxo group; and
B and t are each individually 0, 1 or 2, with the proviso that s and t together are 1 or 2;
R3 is a substituent selected from the group consisting of substituted or unsubstituted (C1-
C6)alkyl, (C1-C6)alkoxy, and phenyl, wherein the substituents are selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halogen and trifluoromethyl;
Tc is 99mTc;
A is a 2- to 8-memibered hydrocarbon biradical, wherein the carbon atoms may be interrupted by one or two heteroatoms selected from O and S;
B is an N-(C1-C4)alkyl group, an NH group, or an optionally substituted piperidin-derived, piperazin-derived, morpholin-derived or pyrrolidin-derived biradical; and
E is selected from the following groups:
Ar-C(=T)r-(GH2)p-, Ar-O-(CH2)q-, Ar-S-(CH2)q-, Ar-C(Ar')-C(=T)r-(CH2)p- and Ar-C(Ar')=, wherein:
p is an integer from 0 to 4;
q is an integer from 0 to 3;
r is an integer from 0 to 1;
T is O or H2; and
Ar and Ar' are each independently unsubstituted or substituted aryl or heteroaryl groups, wherein the aryl or heteroaryl groups are selected from phenyl, pyridyl, pyrrolyl, triazinyl, pyridazinyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, benzofuranyl and benzisoxazolyl, and wherein the substituents are selected from halogen, trifluoromethyl, (C1-C4)alkyl and (C1-C4)alkoxy;
or wherein E together with B constitutes an optionally substituted 2,4-dihydroquinazolyl group attached with its (3-N)atom to A.
Suitable substituents of the piperidin, piperazin, morpholin or
pyrrolidin moiety are halogen, (C1-C3)alkyl and (C1-C3)alkoxy.
The essential features of the invention, which make the labelled substances promising for the intended purpose, are:
- neutral or zero-charged 99mTc - labelled substances to improve their transport through the blood-brain barrier;
- the coupling of a group E, having a serotonin receptor binding activity, with a chelating moiety L for attaching the metal- radionuclide; and particularly
- the use of a well-defined spacing group A and a secondary or tertiary nitrogen atom (symbol B), both essential elements in improving the desired receptor binding affinity.
In the above labelled substances of the invention the symbol A is preferably an alkane, alkoxyalkane or alkylthioalkane biradical having 1 to 6 carbon atoms, a cycloalkylene group having 5 or 6 carbon atoms, or an (alkyl)cycloalkane biradical having 6 to 8 carbon atoms; and E is preferably selected from the following groups: Ar"-C(=T)r-(CH2)p-, Ar"-O-(CH2)q- or Ar"-S-(CH2)q- wherein:
p is an integer from 0 to 4;
q is an integer from 0 to 3;
r is an integer from 0 to 1;
T is O or H2; and
Ar" is a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, (C1-C4)alkyl and (C1-C4)alkoxy.
Preferred chelating group L in the above labelled substances is a metal labelled chelating moiety with the general formula
or
X and X' are each individually O or S;
Y" is S or NR4",
wherein R4" is a hydrogen atom or a (C1-C4)alkyl group; Y'" is NR4' ,
wherein R4' is a covalent bond to A;
R1 and R2 are each independently a biradical of the general formula
wherein:
R6 and R7 are each individually selected from the group consisting of hydrogen, methyl, and fluoro, or wherein R6 and R7 together constitute an oxo group; and
s and t are each individually 0, 1 or 2, with the proviso that s and t together are 1 or 2
R3 is a substituent selected from the group consisting of substituted or unsubstituted (C1-C6)alkyl, (C1-C6)alkoxy, and aryl, wherein the substituents are selected from the group consisting of (C1-C4)alkyl , (C1-C4)alkoxy, halogen and trifluoromethyl;
Tc is 99mTc.
Preferred group B in the above labelled substances of the invention is a group of the general formula
wherein:
Z is CH or N;
R9 and R10 are each individually H or (C1-C3)alkyl, or R9 and R10 form together a biradical of the formula -CH2-CH2-;
u is an integer from 0 to 2;
v is an integer from 0 to 1.
Suitable examples of the zero-charged 99mTc - labelled substances according to the invention are:
The above labelled substances of the invention have been tested in a suitable model experiment that is predictive for in vivo application. This experiment is described in the Examples. From the results of this experiment it will be evident, that the labelled substances of the present invention have properties which make them suitable for the intended use.
The new 99mTc - labelled substances of the invention can be prepared in a manner known per se for related compounds. For this purpose (a) a compound of the general formula
HS - A - B (VTI) wherein the symbols A, B and E have the meanings given hereinbefore, is reacted with technetium-99m in the form of a salt, if necessary in the presence of a reducing agent, or of a chelate bound to a comparatively weak chelator, in the presence of a tridentate coligand of the general formula
HX - R1 - R2 - X'H (IX)
wherein the symbols have the meaning given hereinbefore,
or (b) a compound of the general formula
L" A - B E (VTIA) wherein L"' is a tridentate chelating group of the general formula
HX R1 - Y' X'H (IXA) and the other symbols have the meanings given hereinbefore, is reacted with technetium-99m in the form of a salt, if necessary in the presence of a reducing agent, or of a chelate bound to a comparatively weak chelator, in the presence of a monodentate coligand of the general formula
HS - R3 (VTIIA) wherein R3 has the meaning given hereinbefore.
Suitable examples of monodentate ligands of the general formula VII are represented by the formulas a to e below. These ligands can be combined, for example, with the coligands g to n:
A suitable example of a tridentate ligand of the general formula VIIA is the above ligand of formula m.
As indicated above, it is beyond expectation that in the latter-mentioned complex formation, wherein a tridentate/monodentate ligand combination is involved, the reaction proceeds so selectively to the desired substance, without the formation of by-products, wherein more than one monodentate ligand or more than one tridentate ligand are involved in the chelation of a technetium-99m ion.
The present invention also relates to new ligands for chelating metal atoms, having the general formulas:
HS - A - B (VII) and
L" A - B - E (VIIA) wherein:
L"' is a tridentate chelating group, as defined hereinbefore;
A, B and E have the meanings given hereinbefore, with the proviso that in compound VII B is not an NH group when E is (C3)alkyl phenyl. The invention further relates to a radicpharmaceutical composition, comprising in addition to a pharmaceutically acceptable carrier material and, if desired, at least one pharmaceutically acceptable adjuvant, as the active substance a labelled substance as defined above. The invention also relates to a method for detecting and localizing tissues having serotonin receptors in the body of a warm-blooded living being, in particular in the brain of said being, which comprises (i) administering to said being a composition corrprising, in a quantity sufficient for external imaging, a 99mTc - labelled substance as defined above, and thereupon (ii) subjecting said being to external imaging to determine the targeted sites in the body of said being in relation to the background activity. The method is especially useful to detect and localize tissues having serotonin receptors of the 5-HT2A type. It is frequently not desirable to put the ready-for-use composition at the disposal of the user, in connection with the often poor shelf life of the radiolabelled substance and/or the short half-life of the radionuclide used. In such cases the user will perform the labelling reaction with the radionuclide in the clinical hospital or laboratory. For this purpose the various reaction ingredients are then offered to the user in the form of a so-called cold "kit". It will be obvious that the manipulations necessary to perform the desired reaction should be as simple as possible to enable the user to prepare from the kit the radioactive labelled composition by using the facilities that are at his/her disposal. Therefore the invention also relates to a kit for preparing a radiopharmaceutical composition.
Such a kit according to the present invention may comprise (i) a serotonin receptor binding compound having the general formula VII together with a tridentate ligand of the general formula IX, or a serotonin receptor binding compound of the general formula VIIA together with a monodentate ligand of the general formula VIIIA, to which
compounds, if desired, an inert pharmaceutically acceptable carrier and/or formulating agents and/or adjuvants is/are added, (ii) a reducing agent, and, if desired, a chelator, said ingredients (i) and (ii) optionally being combined, and (iii) instructions for use with a prescription for reacting the ingredients of the kit with 99mTc in the form of a pertechnetate solution.
The radionuclide 99mTc will preferably be added separately in the form of a pertechnetate solution. In that case the kit will comprise a suitable reducing agent and, if desired, a chelator, the former to reduce the pertechnetate or the perrhenate. As a reducing agent may be used, for example, a dithionite or a metallic reducing agent. The ingredients may optionally be combined, provided they are compatible. Such a monocom- ponent kit, in which the combined ingredients are preferably lycphilized, is excellently suitable for being reacted, by the user, with the radionuclide solution. As a reducing agent for the above- mentioned kits is preferably used a metallic reducing agent, for example, Sn(II), Ce(III), Fe(II), Cu(I), Ti(III) or Sb(III); Sn(II) is excellently suitable. The receptor binding compound of the above-mentioned kits may be supplied as a solution, for example, in the form of a physiological saline solution, or in some buffer solution, but is preferably present in a dry condition, for example, in the lycphilized condition. When used as a component for an injection liquid it should be sterile, in which, when the constituent is in the dry state, the user should preferably use a sterile physiological saline solution as a solvent. If desired, the above-mentioned constituent may be stabilized in the conventional manner with suitable stabilizers, for example, ascorbic acid, gentisic acid or salts of these acids, or it may comprise other auxiliary agents, for example, fillers, such as glucose, lactose, mannitol, and the like.
The invention will now be described in greater detail with reference to the following specific Examples. Example I
Synthesis of the above-defined ligand a: 3-(2-mercaptoethyl)-2,4- (1H, 3H)-quinazolindione
Starting from 3-(2-hydroxyethyl)-2,4-(1H,3H)-quinazolindione, which is obtained from methylantranilate (R.J. Grout, M.W. Partridge, J. Chem. Soc. 1960, 3546-3550) the monodentate ligand a is prepared in three steps following a procedure described in DD 298783. The compound a is obtained as a white powder with a m.p. of 189.5-191°C (lit. 192.5- 194.5°C). Example II
Synthesis of the above-defined ligand c: N-2-mercaptoethyl-N-methyl-3-phenylpropylamine.
(a). N-2-hydroxyethyl-N-methyl-3-phenylpropylamine.
To a mixture of N-methylaminoethanol (22.5 g; 0.3 mol) with n-butanol (60 ml) is added powdered K2CO3 (36 g; 0.26 mol). The suspension is heated to 95°C and then a mixture of 3-phenylpropylchloride (38.7 g; 0.25 mol) with n-butanol (25 ml) is added during 2 h .
The resultant reaction mixture is stirred at 100-106°C for 2 h. After cooling to ambient temperature, the solid is removed by filtration. The filtrate is evaporated in vacuo to provide a viscous oil which after fractional distillation yields 36.7 g (76%) of the title product as a colourless oil; b.p. 93-94°C/12Pa; nD 21 = 1.5217. The product is identified by 1H-NMR.
(b). N-2-mercaptoethyl-N-methyl-3-phenylpzopylamine.
To a solution of the above-prepared N-hydrcxyethyl-N-methyl-3-phenylpropylamine (9.66 g; 50 mmol) in methylene chloride (50 ml) is added a solution of HCl in diethyl ether (26.5%; 9.63 g; 70 mmol) . The resultant homogeneous mixture is cooled to -20°C, and thionylchloride (8.3 g; 70 mmol) is added in one portion. The mixture is allowed to reach room temperature and is then refluxed for 5h. The solvent and the excess of thionylchloride are removed in vacuo to give a slightly brown solid which is used without purification.
If desired, the free base can be obtained by treating the crude above product (30 mmol) with a solution of NaHCO3 (5 g in 30 ml water) and extracting the resultant mixture with methylene chloride (1 × 30 ml; 2 × 20 ml). After washing (15% aqueous NaCl, 20 ml) and drying, the filtrate is evaporated to dryness, after which the residue is distilled at 40 Pa to give 5.7 g of the desired product (90%) as a slightly yellow oil. The product is identified by 1H-NMR; nD 21.2 = 1.5184.
To a stirred mixture of the crude hydrochloride, as obtained above, in ethanol (45 ml) is added thiourea (4.18 g; 55 mmol). The reaction mixture is refluxed for 9 h until the starting material disappeared on TLC. After cooling to room temperature, the clear brown solution is evaporated and the viscous residue is dissolved in 50 ml water. While flushing with nitrogen, the solution is heated to 80°C; then solid sodium hydroxide (8 g, 200 mmol) is added during 5 min. The resultant biphasic system is refluxed for 3 h, and, after cooling to room temperature, neutralized by addition of solid KH2PO4 to pH 8-9.
Extraction with methyl-tert.butylether (3 × 25 ml), followed by washing
(satd. aqueous NaCl, 20 ml) and drying, affords a yellow coloured solution which is concentrated in vacuo. The oily residue is finally purified by short-path distillation at 40 Pa, to yield the desired title compound in a yield of 3.84 g (37%) as a colourless liquid; nD 22.5 = 1.5379.
1H-NMR (90 MHz, CDCl3): δ (ppm) = 1.84 [m, 2H, Ph-CH2-CH2-CH2-N]; 2.23 [s, 3H, N-CH3]; 2.30 - 2.80 [m, 8H, Ph-CH2-CH2-CH2-N(CH3)-CH2-CH2-]; 7.21 [m, 5H, Ar-H].
In a corresponding manner ligands b, d and e are prepared.
Example III
Synthesis of the above defined ligand m: 3- [2- (N,N-bis-2-mercaptoethyl) aminoethyl] -2 , 4-1H, 3H-quinazolinedione .
2,3-Dihydro-5H-oxazolo[2,3b]-5-quinazolinone is prepared according to Grout and Partridge (J. Chem. Soc. 1960, 3546).
This product (4.7 g) is converted with diethanolamine (3.15 g) in 50 ml of toluene as the solvent in an autoclave at 155°C within 6 h to 3-[2-(N,N-bis-2-hydroxyethyl)aminoethyl]-2,4-1H,3H-qunazolinedione inayield of 81%. The diol obtained is thereupon converted with thionylchloride (50 g) to the corresponding chloramine-bis(hydrochloride) (yield 100%). This compound is converted in 74% to the corresponding bis (isothiuronium) salt by heating with thiourea (3.85 g) in methoxyethanol during 2 hours. Saponification with aqueous sodium hydroxide produces the desired title ligand in a yield of 25%. Example IV
Synthesis of the above-defined ligand n: N-3[2(N,N-bis-2-mercaptoethyl)]-aminopropyl-N-methyl-3-phenylpropylamine
(a). N(-3-hydroxypropyl)-3-phenylpropylamine
To a suspension of potassium carbonate (41.5 g, 0.3 mol) in n-butanol (250) is added 3-aminopropanol (42.1 g, 0.56 mol). The mixture is heated to 105-110°C, and then a mixture of 3-phenylpropylchloride (43.2g, 0.28 mol) with n-butanol (40 ml) is added during 3 hours. The resultant reaction mixture is refluxed for 4 hours.
After cooling to ambient temperature (22°C) the solid is removed by filtration and washed with CHCl3 (2 × 60 ml). The filtrate is evaporated to give an oil which is fractionally distilled to yield 39.6 g (73%) N-3-hydroxypropyl)-3-phenylpropylamine as a low melting solid; bp. 114-115°C/18 Pa; m.p. 37°C.
(b) N-(3-hydroxypropyl)-N-methyl-3-phenylpropylamine
N-(3-hydroxypropyl)-3-phenylpropylamine (23.2 g, 012 mol) is dissolved in formic acid (85%; 33g, 0.6 mol). To the sightly yellow colored mixture an aqueous solution of formaldehyde (36%; 11.2 ml, 0.144 mol) is added.
The whole is heated under stirring at 100 - 110°C. After 8 hours,
(meanwhile the evolution of CO2 has ceased) the mixture is cooled and concentrated in vacuo at 50°C.
The residue is acidified with HCl (2N, 30 ml) and after standing at 22°C for 3 days, NaOH (25%, 50 ml) is added to the homogeneous mixture. The
oil formed is extracted with MTBE (2 × 60 ml) and dried over NaOH pellets. The solvent is evaporated and the remaining product purified by fractional distillation to give 22.5 g (90%) N-(3-hydroxypropyl)-N-methyl-3-phenylpropylamine as a colorless viscous liquid; bp. 102 - 103°/12 Pa (Lit: 147.5°C/5 Torr).
The diamine is prepared by amination of the chloro intermediate using the sodium diformylamide method described by Yinglen and Hongwen (Synthesis 1990, 112 - 124).
(c). N(-3-aminopropyl)-N-methyl-3-phenylpropylamine
To a solution of N-(hydroxypropyl)-N-methyl-3-phenylpropylamine (12.4 g; 60 mmol) in chloroform (50 ml) an etherical solution of hydrogen chloride (22%, 13.2 g, 80 mmol) is added. The resultant homogeneous mixture is cooled to -20°C and thionychloride (10 g, 84 mmol) is added in one portion. The mixture is allowed to warm to room temperature and then refluxed for 3 - 5 h. The solvent and the excess of thionylchloride are removed in vacuo to give a slightly brown solid which is used without purification.
The free base is obtained by treating the crude product with a solution of NaHCO3 (8 g in 40 ml water) and extracting the resultant mixture with chloroform (1 × 35 ml, 2 × 20 ml). After washing (15% NaCl, 20 ml) and drying (MgSO4) the filtrate is evaporated and the residue is distilled at 40 Pa to give 12.5 of slightly yellow oil.
A mixture of this chloro derivative (12.4 g, 55.2 mmol), sodium diformylamide (6.3 g, 66.3 mmol) and dry DMF (20 ml) is stirred at 120 - 125°C for 7 hours. After cooling to ambient temperature the solid is removed by filtration and washed with CHCl 3 (2 × 10 ml). The combined filtrate is evaporated and the residue is dissolved in 4 N HCl (40 ml) The homogenous mixture is refluxed for 2 hours and evaporated to near dryness. The residue is treated with 25 % NaOH (40 ml) and the free alkylamine liberated is extracted with MTBE (3 × 25ml). The combined extract is dried (NaOH) and evaporated. The crude product obtained is purified by distillation to give 10.2 g (82.1% overall yield); b.p. 74-75°C/9 Pa, n22.0 D = 1.5160 (Lit. US 3,211,789; C.A. 1966, 64, 5011e.: b.p. 154 - 6°C/10 torr, n200 D = 1.15140).
(d). N-3-[2-(N,N-bis-2-mercaptoethyl)]-aminopropyl-N-methyl-3-phenylpropylamine n
The final product is prepared according to J.L. Corbin et al. (Inorg. Chim. Acta 90 (1984) 41-51).
A solution of N-(3-aminopropyl)-N-methyl-3-phenylproylamine (2g, 0.01 mol) in 40 ml of dry toluene is mixed with a solution of ethylene sulfide (1.3g, 0.021 mol) in 30 ml of dry toluene and allowed to stand overnight (sealed tube, argon flushed). The reaction mixture is heated to 130°C (bath temperature) for 15 h, cooled, and filtered to removed a small amount of polymer product. The solvent is removed and the crude product precipitated as hydrochloride. Recrystallization from methanol/diethyl ether yields a as a white powder.
Example V
Labelling procedure.
A vial containing a lyophilized mixture of 100 mg sodium gluconate and 0.5 mg of SnCl2 is reconstituted with a mixture of 3ml of water and 0.5 mg of 99mTc-pertechnetate (ca. 500 MBq). The resulting 99mTc-gluconate complex is added to 1 ml of an acetonitrilic solution containing equimolar amounts of the tridentate ligand g (0.015 mmol) and the monodentate ligand s. (0.015 mmol). After agitating the mixture for 20 minutes, the pH is adjusted to approximately 9 with 0.1 N NaOH. Then the aqueous solution is extracted with 1 ml of diethyl ether. About 90% of the activity is recovered. The organic phase is washed twice with 1 ml of water and dried over Na2SO4.
For biochemical studies the solvent is carefully evaporated and the residue is redissolved in DMSO. The labelled substance 1, as shown hereinbefore, is obtained.
In a corresponding manner the labelled substances 2, 3 and 4 are obtained, using tridentate ligand g in combination with monodentate ligands d, b and e, respectively, as the starting compounds. The same procedure applies for technetium complex 5, using the tridentate ligand a in combination with a monodentate thiol, e.g. 4-methoxybenzenthiol.
Example VI
Biochemical studies.
The quantitative binding characteristics in vitro are determined with the aid of inhibition experiments. Substances 1-6 mentioned above are used.
The cortex of rat brain is homogenized in 10 volumes of ice-cold Tris-buffer solution (50 mM Tris-HCl, pH 7.6) with an Ultra-TurraxR T25 homogenizer. The homogenate is centrifuged at 20,000 g for 10 min. The resulting pellet is resuspended with the Ultra-Turrax and centrifuged again at 20,000 g for 10 min. After repeating the same procedure, the pellet is resuspended in 10 volumes of buffer and stored at -20°C until use in the binding studies.
The time dependency of ketanserin binding is studied on these membrane preparations (0.013 mg/ml protein). The samples are incubated at 23°C for various times with ketanserin hydrochloride [ethylene-3H] (2356.9 GBq/mmol) in the presence and absence of 1 μM unlabelled mianserin, a well-known serotonin receptor antagonist just as ketanserin. For inhibition studies the samples are incubated at 23°C for 60 min. The binding assays are terminated by rapid filtration through GF/B glass fiber filters. The filters are rapidly washed with four 4-ml portions of ice-cold buffer, transferred to 10 ml of scintillation fluid (uJtima- GoldR) and analysed for radioactivity. Aliquots of the incubation fluid are measured as well. Corrections are made for binding 3H-ketanserin to the filters. The protein content of the membrane suspensions is estimated according to the method of Lowry et al. (J. Biol. Chem. 1951, 123, 265).
Conclusion:
The binding studies show that the binding constants of substances 1-6 are of the same order of magnitude as the binding constant of ketanserin, and are therefor promising metal-labelled compounds for imaging.
Claims
1. A zero-charged 99mTc - labelled substance having a serotonin receptor binding activity, wherein the serotonin receptor binding compound is represented by the general formula
L - A - B - E (I) wherein:
L is a metal labelled chelating moiety with the general formula
or
wherein:
X and X' are each individually O or S;
Y is O, S, Se, NR4, PR4 or -C(R4)=N-,
wherein R4 is a hydrogen atom or a (C1-C6)alkyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, oxo, [N-mono- or N,N-di(C1- C3)alkyl]-amino, (C1-C3)alkyl, (C1-C3)alkoxy and optionally substituted phenyl;
Y' is NR,' or PR,' or -C (R4 =N- ,
wherein R4 ' is a covalent bond to A;
R1 and R2 are each independently a biradical of the general formula
wherein:
R6, R7 or R8 are each individually selected from the group consisting of hydrogen, (C1-C3) alkyl, (C1- C3)alkoxy and fluoro, or wherein R6 and R7 together constitute an oxo group; and
s and t are each individually 0, 1 or 2, with the proviso that s and t together are 1 or 2;
R3 is a substituent selected from the group consisting of substituted or unsubstituted (C1- C6)alkyl, (C1-C6) alkoxy, and phenyl, wherein the substituents are selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halogen and trifluoromethyl;
Tc is 99mTc;
A is a 2- to 8-membered hydrocarbon biradical, wherein the carbon atoms may be interrupted by one or two heteroatoms selected from O and S;
B is an N-(C1-C4)alkyl group, an NH group, or an optionally substitutedpiperidin-derived, piperazin-derived, morpholin-derived or pyrrolidin-derived biradical; and
E is selected from the following groups: Ar-C(=T)r-(CH2)p-, Ar-O-(CH2)q-, Ar-S-(CH2)q-, Ar-C(Ar')-C(=T)r-(CH2)p- and Ar-C(Ar')=, wherein:
p is an integer from 0 to 4;
q is an integer from 0 to 3;
r is an integer from 0 to 1;
T is O or H2; and
Ar and Ar' are each independently unsubstituted or substituted aryl or heteroaryl groups, wherein the aryl or heteroaryl groups are selected from phenyl, pyridyl, pyrrolyl, triazinyl, pyridazinyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, benzofuranyl and benzisoxazolyl, and wherein the substituents are selected from halogen, trifluoromethyl, (C1-C4)alkyl and (C1-C4) alkoxy;
or wherein E together with B constitutes an optionally substituted 2,4-dihydroquinazolyl group attached with its (3-N)atom to A.
2. A labelled substance as claimed in claim 1, wherein the serotonin receptor binding compound has the general formula
L - A' - B - E' (IA) wherein:
L and B have the meanings given in claim 1;
A' is an alkane, alkoxyalkane or alkylthioalkane biradical having 1 to 6 carbon atoms, a cycloalkylene group having 5 or 6 carbon atoms, or an (alkyl)cycloalkane biradical having 6 to 8 carbon atoms; and
E' is selected from the following groups:
Ar"-C(=T)r-(CH2)p-, Ar"-O-(CH2)q- or Ar"-S-(CH2)q- wherein:
p is an integer from 0 to 4;
q is an integer from 0 to 3;
r is an integer from 0 to 1;
T is O or H2; and
Ar" is a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, (C1-C4) alkyl and (C1-C4) alkoxy.
3. A labelled substance as claimed in claim 2, wherein the serotonin receptor binding compound has the general formula
L' - A' - B' - E' (IB) wherein:
A' and E' have the meanings given in claim 2;
L' is a metal labelled chelating moiety with the general formula
or 
X and X' are each individually O or S;
Y" is S or NR4"
wherein R4" is a hydrogen atom or a (C1-C4)alkyl group; Y'" is NR4' ,
wherein R4' is a covalent band to A;
R1 and R2 are each independently a biradical of the general formula
wherein:
R6 and R7 are each individually selected from the group consisting of hydrogen, methyl, and fluoro, or wherein R6 and R7 together constitute an oxo group; and
s and t are each individually 0, 1 or 2, with the proviso that s and t together are 1 or 2
R3 is a substituent selected from the group consisting of substituted or unsubstituted (C1-C6)alkyl, (C1-C6) alkoxy, and aryl, wherein the substituents are selected from the group consisting of (C1-C4) alkyl, (C1-C4)alkoxy, halogen and trifluoromethyl;
Tc is 99mTc;
B' is a group of the general formula 
wherein:
Z is CH or N;
R9 and R10 are each individually H or (C1-C3)alkyl, or R9 and R10 form together a biradical of the formula
-CH2-CH2- ;
u is an integer from 0 to 2;
v is an integer from 0 to 1.
4. A method of preparing a 99mTc - labelled substance as claimed in claim 1, characterized in that (a) a compound of the general formula
HS - A - B - E (VTI) wherein the symbols A, B and E have the meanings given in claim 1, is reacted with technetium-99m in the form of a salt, if necessary in the presence of a reducing agent, or of a chelate bound to a comparatively weak chelator, in the presence of a tridentate coligand of the general formula
HX - R1 - Y - R2 - X'H (IX) wherein the symbols have the meaning given in claim 1,
or (b) a compound of the general formula
L"' - A - B - E (VIIA) wherein L"' is a tridentate chelating group of the general formula
HX - R1 - Y' - R2 - X'H (IXA) and the other symbols have the meanings given in claim 1, is reacted with technetium-99m in the form of a salt, if necessary in the presence of a reducing agent, or of a chelate bound to a comparatively weak chelator, in the presence of a monodentate coligand of the general formula
HS - R3 (VIIIA) wherein R3 has the meaning given in claim 1.
5. A compound to be used for the method according to claim 4, having the general formula
HS - B - E (VII) wherein the symbols have the meanings given in claim 1, with the proviso that B is not an NH group when E is (C3) alkyl phenyl.
6. A ccmpound to be used for the method according to claim 5, having the general formula
L"' - A - B - E (VIIA) wherein the L"' has the meaning given in claim 4 and the other symbols have the meanings given in claim 1.
7. A radiopharmaceutical composition, comprising in addition to a pharmaceutically acceptable carrier material and, if desired, at least one pharmaceutically acceptable adjuvant, as the active substance a labelled substance as claimed in claim 1, 2 or 3.
8. A method for detecting and localizing tissues having serotonin receptors in the body of a warm-blooded living being, in particular in the brain of said being, which comprises (i) administering to said being a composition comprising, in a quantity sufficient for external imaging, a 99mTc - labelled substance as claimed in claim 1, 2 or 3, and thereupon (ii) subjecting said being to external imaging to determine the targeted sites in the body of said being in relation to the background activity.
9. A method according to claim 8, characterized in that said serotonin receptors are of the 5-HT2A type.
10. A kit for preparing a radicpharmaceutical composition, comprising (i) a serotonin receptor binding compound having the general formula VII together with a tridentate ligand of the general formula IX, or a serotonin receptor binding compound of the general formula VIIA together with a monodentate ligand of the general formula VIIIA, to which compounds, if desired, an inert pharmaceutically acceptable carrier and/or formulating agents and/or adjuvants is/are added, (ii) a reducing agent, and, if desired, a chelator, said ingredients (i) and (ii) optionally being combined, and (iii) instructions for use with a prescription for reacting the ingredients of the kit with 99mTc in the form of a pertechnetate solution. Abstract
The invention relates to a zero-charged 99mTc - labelled substance having a serotonin receptor binding activity, wherein the serotonin receptor binding compound is represented by the general formula
L - A - B - E (I) wherein:
L is a chelating moiety selected consisting of a tridentate/monodentate chelating combination;
A is a 2- to 8-membered hydrocarbon biradical, wherein the carbon atoms may be interrupted by one or two heteroatoms selected from O and S;
B is an N-(C1-C4)alkyl group, an NH group, or an optionally substituted piperidin-derived, piperazin-derived, morpholin-derived or pyrrolidin-derived biradical; and
E is selected from the following groups: Ar-C(=T)r-(CH2)p-, Ar-O-(CH2)q-, Ar-S-(CH2)q-, Ar-C(Ar')-C(=T)r-(CH2)p- and Ar-C(Ar,)=, wherein:
p is an integer from 0 to 4;
q is an integer from 0 to 3;
r is an integer from 0 to 1;
T is O or H2; and
Ar and Ar' are each independently unsubstituted or substituted aryl or heteroaryl groups, wherein the aryl or heteroaryl groups are selected from phenyl, pyridyl, pyrrolyl, triazinyl, pyridazinyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, benzofuranyl and benzisoxazolyl, and wherein the substituents are selected from halogen, trifluoromethyl, (d-C4) alkyl and (d-C4) alkoxy;
or wherein E together with B constitutes an optionally substituted 2,4- dihydroquinazolyl group attached with its (3-N)atom to A.
wherein said serotonin receptor binding compound is labelled with technetium-99m in the form of oxotechnetium(V), said technetium being attached to said cotpound by means of said chelating moiety.
The invention also relates to a method of preparation of said labelled substance, a radicpharmaceutical composition cotrprising said labelled substance, a method for detecting and localizing tissues having serotonin receptors with the aid of said labelled substance and a kit for preparing a radiopharmaceutical composition containing said labelled substance.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95200771 | 1995-03-28 | ||
| EP95200771.4 | 1995-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996030054A1 true WO1996030054A1 (en) | 1996-10-03 |
Family
ID=8220136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/004239 Ceased WO1996030054A1 (en) | 1995-03-28 | 1996-03-27 | 99mTc - LABELLED SEROTONIN RECEPTOR BINDING SUBSTANCES |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1996030054A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1027011A4 (en) * | 1997-10-28 | 2002-03-06 | Vivus Inc | Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation |
| US6359119B1 (en) | 2000-05-24 | 2002-03-19 | Mallinckrodt Inc. | Formulation of Tc and Re carbonyl complexes using stannous ion as the reductant for pertechnetate and perrhenate |
| ES2170027A1 (en) * | 2000-12-01 | 2002-07-16 | Univ Barcelona Autonoma | TECHNICAL AND RENIO COMPOUNDS WITH TABLE FOR RADIOPHARMACEUTICAL APPLICATIONS. |
| WO2004004635A3 (en) * | 2002-07-02 | 2004-07-01 | Univ Texas | Radiolabeled compounds and liposomes and their methods of making and using the same |
| US10556013B2 (en) | 2017-06-20 | 2020-02-11 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| US12318382B2 (en) | 2018-10-17 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957728A (en) * | 1989-05-19 | 1990-09-18 | University Of Cincinnati | Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans |
| US4980147A (en) * | 1984-06-25 | 1990-12-25 | University Of Utah Research Foundation | Radiolabeled technetium chelates for use in renal function determinations |
| US5075099A (en) * | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5382654A (en) * | 1992-02-05 | 1995-01-17 | Mallinckrodt Medical, Inc. | Radiolabelled peptide compounds |
-
1996
- 1996-03-27 WO PCT/US1996/004239 patent/WO1996030054A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980147A (en) * | 1984-06-25 | 1990-12-25 | University Of Utah Research Foundation | Radiolabeled technetium chelates for use in renal function determinations |
| US5075099A (en) * | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US4957728A (en) * | 1989-05-19 | 1990-09-18 | University Of Cincinnati | Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans |
| US5382654A (en) * | 1992-02-05 | 1995-01-17 | Mallinckrodt Medical, Inc. | Radiolabelled peptide compounds |
Non-Patent Citations (8)
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1027011A4 (en) * | 1997-10-28 | 2002-03-06 | Vivus Inc | Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation |
| US6359119B1 (en) | 2000-05-24 | 2002-03-19 | Mallinckrodt Inc. | Formulation of Tc and Re carbonyl complexes using stannous ion as the reductant for pertechnetate and perrhenate |
| ES2170027A1 (en) * | 2000-12-01 | 2002-07-16 | Univ Barcelona Autonoma | TECHNICAL AND RENIO COMPOUNDS WITH TABLE FOR RADIOPHARMACEUTICAL APPLICATIONS. |
| WO2004004635A3 (en) * | 2002-07-02 | 2004-07-01 | Univ Texas | Radiolabeled compounds and liposomes and their methods of making and using the same |
| AU2003241598B2 (en) * | 2002-07-02 | 2009-11-05 | Nanotx Corp. | Radiolabeled compounds and liposomes and their methods of making and using the same |
| US7718160B2 (en) | 2002-07-02 | 2010-05-18 | The Board Of Regents Of The University Of Texas System | Radiolabeled compounds and liposomes and their method of making and using same |
| US10556013B2 (en) | 2017-06-20 | 2020-02-11 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US10918728B2 (en) | 2017-06-20 | 2021-02-16 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US10953102B2 (en) | 2017-06-20 | 2021-03-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US11376330B2 (en) | 2017-06-20 | 2022-07-05 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US11844840B2 (en) | 2017-06-20 | 2023-12-19 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US12318453B2 (en) | 2017-06-20 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US12318382B2 (en) | 2018-10-17 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US12065410B2 (en) | 2020-06-30 | 2024-08-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US12110275B2 (en) | 2020-06-30 | 2024-10-08 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11746090B2 (en) | 2020-06-30 | 2023-09-05 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| US12285428B2 (en) | 2021-05-03 | 2025-04-29 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7250525B2 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
| US5744121A (en) | Serotonin (5-HT1A) receptor ligands and imaging agents | |
| Kung et al. | Dopamine D-2 receptor imaging radiopharmaceuticals: Synthesis, radiolabeling and in vitro binding of (R)-(+)-and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide | |
| KR100451077B1 (en) | Dopamine and Serotonin Transporter Ligands and Imaging Agents | |
| FI91747C (en) | Etherisonitriles and radiolabelled complexes thereof | |
| EP0381713B1 (en) | Diaminedithiol chelating agents for radiopharmaceuticals | |
| JPH04212099A (en) | Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing biochemically active groups | |
| WO2007002540A2 (en) | Radiolabeled-pegylation of ligands for use as imaging agents | |
| AU2002323417A1 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
| AU640350B2 (en) | Novel tc-99m complexes | |
| WO1996030054A1 (en) | 99mTc - LABELLED SEROTONIN RECEPTOR BINDING SUBSTANCES | |
| US5993774A (en) | Metal-oxime chelates for use as radiopharmaceutical agents | |
| US5330737A (en) | Nitrogen-sulfur ligands as opiate receptor drug mimics | |
| US5700446A (en) | Synthesis of ferrocenyl phenyltropane analogs and their radio-transformation to technetium neuroprobes for mapping monoamine reuptake sites | |
| EP0515670B1 (en) | Hexadentate ligands useful in radiographic imaging agents | |
| Pietzsch et al. | Synthesis and autoradiographic evaluation of a novel high-affinity Tc-99m ligand for the 5-HT2A receptor | |
| US5420321A (en) | Tris(isonitrile)copper(i) sulfates for preparing radionuclide complexes | |
| JP3083157B2 (en) | Radiometal complexes localized in anoxic tissues | |
| DE69515302T2 (en) | Aromatic amine-substituted ligands with bridged nitrogen and sulfur donor atoms for image formation | |
| KR100762930B1 (en) | Technetium-labeled arylpiperazine derivatives for serotonin receptor imaging | |
| US6384232B1 (en) | Methods of synthesizing heteroatom-bearing ligands and intermediate used thereof | |
| JP2000219674A (en) | New aralkyl guanidine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |